LSTA
Lisata Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Stock Price Surged Significantly
MACD Golden Cross
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LSTA
Lisata Therapeutics, Inc.
A clinical-stage pharmaceutical company that developing innovative therapies for advanced solid tumors
110 Allen Road, 2nd Floor, Basking Ridge, New Jersey 07920
--
Lisata Therapeutics, Inc., incorporated under the laws of the State of Delaware in the name of Fidelity Medical Services Ltd., was incorporated in September 1980 and commenced operations in the current market in January 2006. The Company is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of solid tumors and other critical diseases. The company's lead research candidate, LSTA 1 (formerly CEND-1), is designed to activate a new uptake pathway that enables combined-administered or bundled anticancer drugs to penetrate solid tumors more effectively.
Earnings Call
Q2/2025
Estimate EPS-0.65
Actual EPS-0.54
Estimate Revenue--
Actual Revenue70.00K
Lisata Therapeutics Q2 2025: Key Contradictions in ASCEND Trial Insights and Financial Projections
Aug 08,2025 03:14
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
LSTA has released its 2025 Q3 earnings. EPS was reported at -0.49, versus the expected -0.54, beating expectations. The chart below visualizes how LSTA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
